419 related articles for article (PubMed ID: 21898351)
1. A two-stage approach to the treatment of hyperuricemia in gout: the "dirty dish" hypothesis.
Perez-Ruiz F; Herrero-Beites AM; Carmona L
Arthritis Rheum; 2011 Dec; 63(12):4002-6. PubMed ID: 21898351
[TBL] [Abstract][Full Text] [Related]
2. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?
Li-Yu J; Clayburne G; Sieck M; Beutler A; Rull M; Eisner E; Schumacher HR
J Rheumatol; 2001 Mar; 28(3):577-80. PubMed ID: 11296962
[TBL] [Abstract][Full Text] [Related]
3. Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study.
Perez-Ruiz F; Atxotegi J; Hernando I; Calabozo M; Nolla JM
Arthritis Rheum; 2006 Oct; 55(5):786-90. PubMed ID: 17013833
[TBL] [Abstract][Full Text] [Related]
4. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.
Perez-Ruiz F; Calabozo M; Pijoan JI; Herrero-Beites AM; Ruibal A
Arthritis Rheum; 2002 Aug; 47(4):356-60. PubMed ID: 12209479
[TBL] [Abstract][Full Text] [Related]
5. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
[TBL] [Abstract][Full Text] [Related]
6. [Establishment of therapeutic goal and plan of gout and asymptomatic hyperuricemia].
Fujimori S
Nihon Rinsho; 2008 Apr; 66(4):729-35. PubMed ID: 18409523
[TBL] [Abstract][Full Text] [Related]
7. Long-term remission from gout associated with fenofibrate therapy.
Hepburn AL; Kaye SA; Feher MD
Clin Rheumatol; 2003 Feb; 22(1):73-6. PubMed ID: 12605325
[TBL] [Abstract][Full Text] [Related]
8. [Usefulness of combination treatment using allopurinol and benzbromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of oxypurinol].
Ohno I; Okabe H; Yamaguchi Y; Saikawa H; Uetake D; Hikita M; Gomi H; Ichida K; Hosoya T
Nihon Jinzo Gakkai Shi; 2008; 50(4):506-12. PubMed ID: 18546882
[TBL] [Abstract][Full Text] [Related]
9. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.
Dalbeth N; Kumar S; Stamp L; Gow P
J Rheumatol; 2006 Aug; 33(8):1646-50. PubMed ID: 16783857
[TBL] [Abstract][Full Text] [Related]
10. The management of gout at an academic healthcare center in Beijing: a physician survey.
Fang W; Zeng X; Li M; Chen LX; Schumacher HR; Zhang F
J Rheumatol; 2006 Oct; 33(10):2041-9. PubMed ID: 17014019
[TBL] [Abstract][Full Text] [Related]
11. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy.
Becker MA; MacDonald PA; Hunt BJ; Lademacher C; Joseph-Ridge N
Nucleosides Nucleotides Nucleic Acids; 2008 Jun; 27(6):585-91. PubMed ID: 18600509
[TBL] [Abstract][Full Text] [Related]
12. Serum urate levels and gout flares: analysis from managed care data.
Sarawate CA; Patel PA; Schumacher HR; Yang W; Brewer KK; Bakst AW
J Clin Rheumatol; 2006 Apr; 12(2):61-5. PubMed ID: 16601538
[TBL] [Abstract][Full Text] [Related]
13. [Other antihyperuricemic agents].
Ogino K; Igawa O; Hisatome I
Nihon Rinsho; 2008 Apr; 66(4):754-7. PubMed ID: 18409527
[TBL] [Abstract][Full Text] [Related]
14. Gout: an update.
Eggebeen AT
Am Fam Physician; 2007 Sep; 76(6):801-8. PubMed ID: 17910294
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure gout.
Yue CS; Huang W; Alton M; Maroli AN; Waltrip RW; Wright D; Marco MD
J Clin Pharmacol; 2008 Jun; 48(6):708-18. PubMed ID: 18420531
[TBL] [Abstract][Full Text] [Related]
16. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout.
Feher MD; Hepburn AL; Hogarth MB; Ball SG; Kaye SA
Rheumatology (Oxford); 2003 Feb; 42(2):321-5. PubMed ID: 12595630
[TBL] [Abstract][Full Text] [Related]
17. [Therapy of hyperuricemia and gout].
Pöllmann G; Kullich W; Klein G
Wien Med Wochenschr; 1997; 147(16):382-7. PubMed ID: 9446417
[TBL] [Abstract][Full Text] [Related]
18. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Palo WA; Eustace D; Vernillet L; Joseph-Ridge N
Arthritis Rheum; 2005 Mar; 52(3):916-23. PubMed ID: 15751090
[TBL] [Abstract][Full Text] [Related]
19. The effect of control and self-medication of chronic gout in a developing country. Outcome after 10 years.
Darmawan J; Rasker JJ; Nuralim H
J Rheumatol; 2003 Nov; 30(11):2437-43. PubMed ID: 14677190
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.
Reinders MK; van Roon EN; Jansen TL; Delsing J; Griep EN; Hoekstra M; van de Laar MA; Brouwers JR
Ann Rheum Dis; 2009 Jan; 68(1):51-6. PubMed ID: 18250112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
